Description: Learn about Tresiba® (insulin degludec), a once-daily, long-acting basal insulin for patients over 1 year of age with type 1 or type 2 diabetes. Read Important Safety & Prescribing Info.
Tresiba ® is a long-acting basal insulin indicated to improve glycemic control in patients 1 year of age and older with diabetes. 1
The majority of commercially insured patients pay $35 or less per monthly co-pay for Tresiba ®1,a
Starting in January 2023, all Medicare Part D patients with Tresiba ® formulary coverage will pay no more than $35 per 30-day supply